NASDAQ NMS - GLOBAL MARKET · UNCY
+1.05% · +$0.0500 · Vol 1.1M
Market closed · last close 4:00 PM ET · price as of 18:38:06 ET
Unicycive Therapeutics Inc

Unicycive Therapeutics Inc

Biotechnology
$4.82
Card
Relationship Map

Follow $UNCY

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $UNCY by email

Veridion Score

BETALOW CONF · 6 of 6 factors measuredMethodology
UNCY
Unicycive Therapeutics Inc
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

44/ 100
Veridion Score
Lower range · LOW confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is UNCY moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading UNCY catalysts
About Unicycive Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
22
Country
US

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.80
Day high
$4.85
Day low
$4.76
Previous close
$4.77
52W high
$8.56
-43.69% from high
52W low
$3.74
22% of range
Market cap
$132.9M
EPS
$-1.4500
Beta
0.29
Shares out
27.9M
Volume
1.1M
1.37× rel vol
Avg volume
808K
VWAP
$4.80
Price history computed in-house
1W
-8.88%
1M
-11.56%
3M
-29.64%
1Y
+21.72%
YTD
-16.46%
SMA 50 $5.23 · below
SMA 200 $6.38 · below
52W position 22%

UNCY overview

Veridion Score
44
Registered · 2026-09-18
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around UNCY.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading UNCY Form 4 filings
Public disclosures

Congress activity in UNCY

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for UNCY in the cached public ledger.

Federal contracts

UNCY contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for UNCY in this window.
Lobbying spend

UNCY lobbying filings, year to date.

Registered lobbying filings matched to Unicycive Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for UNCY in this window.
Loading news for UNCY
Analyst ratings
Sovereign unlock shows live analyst consensus for UNCY.
Options
Sovereign unlock shows live options positioning for UNCY.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.